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Abbreviations 
 
DES  Distal esophageal spasm 
EGJ  Esophago-gastric junction 
EoE  Eosinophilic esophagitis 
ERD  Erosive reflux disease 
FD  Functional dyspepsia 
GER  Gastro-esophageal reflux 
GERD  Gastro-esophageal reflux disease 
HH  Hiatal hernia 
IBS  Irritable bowel syndrome 
ISDE  International diseases of the esophagus 
LES  Lower esophageal sphincter 
MRS  Multiple rapid swallow 
NCCP  Non-cardiac chest pain 
NERD  Non-erosive reflux disease 
PEH  Para-esophageal hernia 
PPI  Proton pump inhibitor 
 
  
Abstract 
Objective: Anti-reflux surgery can be proposed in patients with gastro-esophageal reflux 
disease, especially when proton pump inhibitor use leads to incomplete symptom 
improvement. However, to date, international consensus guidelines on the clinical criteria 
and additional technical examinations used in patient selection for anti-reflux surgery are 
lacking. We aimed at generating key recommendations in the selection of patients for anti-
reflux surgery.  
Design: We included 35 international experts (gastroenterologists, surgeons and 
physiologists) in a Delphi process and developed 37 statements that were revised by the 
Consensus Group, to start the Delphi process. Three voting rounds followed where each 
statement was presented with the evidence summary. The panel indicated the degree of 
agreement for the statement. When 80% of the Consensus Group agreed (A+/A) with a 
statement, this was defined as consensus. All votes were mutually anonymous. 
Results: Patients with heartburn with a satisfactory response to PPIs, patients with a hiatal 
hernia (HH), patients with esophagitis LA grade B or higher and patients with Barrett’s 
esophagus are good candidates for anti-reflux surgery. An endoscopy prior to anti-reflux 
surgery is mandatory and a barium swallow should be performed in patients with suspicion 
of a HH or short esophagus. Esophageal manometry is mandatory to rule out major motility 
disorders. Finally, esophageal pH (+/- impedance) monitoring off PPI is mandatory to select 
patients for anti-reflux surgery, if endoscopy is negative for unequivocal reflux esophagitis.  
Conclusion: With the ICARUS guidelines, we generated key recommendations for selection 
of patients for anti-reflux surgery.  
Keywords: anti-reflux surgery, patient selection, Delphi process 
  
Introduction 
Gastro-esophageal reflux disease (GERD) occurs when the reflux of (duodeno)-gastric 
contents into the esophagus causes troublesome symptoms and/or tissue damage 
(esophagitis, stricture, Barrett’s esophagus).1 GERD is a very common condition with a 
prevalence of 20% in the Western population. It may present with a broad spectrum of 
symptoms, subdivided into typical, esophageal manifestations (heartburn and regurgitation) 
and a variety of atypical, extra-esophageal symptoms, such as chronic cough, wheezing and 
hoarseness. Typical and atypical symptoms can co-exist in the same patient.2–4 
 
Proton pump inhibitors (PPIs) are the first line medical treatment for patients with GERD, 
and PPI therapy has proven to be highly effective in healing esophagitis.5,6 However, efficacy 
rates for symptom relief are significantly lower, with between 10 and 40% of GERD patients 
failing to respond symptomatically, either partially or completely.6 Underlying mechanisms 
behind symptom generation in refractory GERD are the presence of weakly acidic and bile 
reflux, residual acid reflux, esophageal hypersensitivity and psychological co-morbidities.6  
When lifestyle modifications, dietary changes and especially when medical treatment 
(antacids, histamine 2 (H2-) receptor antagonist and PPIs) for GERD fails, anti-reflux surgery 
can be proposed. Anti-reflux surgery can also be recommended in case of intolerance to PPIs 
or as an alternative in anticipated long-term medical therapy in young GERD patients. While 
medical treatment is focused on reducing the acidity of the refluxate, classic anti-reflux 
surgery generates a mechanical and functional barrier preventing reflux from gastric 
contents into the esophagus.  
Several long term follow-up studies looking at recurrence rates of reflux symptoms have 
been published over the last years. A recent Swedish study followed 2655 patients who 
underwent primary laparoscopic anti-reflux surgery for a mean of 5.1 years and 
demonstrated recurrence of reflux in 470 (17.7%) of patients. Risk factors for recurrence of 
reflux were female gender, older age and co-morbidity.7 A 5-year follow up study, the LOTUS 
trial, demonstrated that a standardized laparoscopic Nissen fundoplication performed in 
expert centers and treatment with esomeprazole had similar outcome results concerning 
treatment failure rate, albeit that relief of heartburn was somewhat superior after surgery. 
The vast majority of patients achieved and remained in remission after 5 years, both in the 
surgical group as well as in the medical treatment group.8 However, the LOTUS study only 
enrolled patients with complete symptom control on esomeprazole and the results are not 
necessarily applicable to the group of patients with insufficient symptom control on PPIs, 
which constitutes a risk factor for a poor outcome.9   
 
Selection of patients for anti-reflux surgery is traditionally based on the symptom pattern 
(preferably typical GERD symptoms), on the response to PPIs (at least partial response) and 
on the result of esophageal pH or pH-impedance monitoring (pathological acid exposure in 
the absence of acid suppressive therapy).9,10 In 2013, a US-based consensus concerning pre-
operative diagnostic workup before anti-reflux surgery was published, however, this was a 
national consensus (the expert panel consisted of only American experts), achieved through 
informal voting 11.  
The literature reports that outcome of anti-reflux surgery is influenced by anatomical and 
technical aspects as assessed by endoscopy, radiology, manometry and reflux monitoring, 
but also by demographic and co-morbidity factors such as the presence of irritable bowel 
syndrome (IBS), functional dyspepsia (FD), anxiety and depression. However, it is unclear to 
which extent these aspects should influence decisions to perform anti-reflux surgery, and to 
date global consensus guidelines on the clinical criteria and additional technical 
examinations used in patient selection for anti-reflux surgery are lacking.  
 
Therefore, the aim of this project was to develop a global and multidisciplinary consensus on 
patient characteristics and preoperative examinations that could offer the clinician guidance 
in selecting adult GERD patients for classic anti-reflux surgery and possibly in adapting the 
technical aspects of the intervention in order to optimize clinical outcome. 
 
Methods 
A Delphi process was started, with support from the International Society for Diseases of the 
Esophagus (ISDE), to develop consensus statements for preoperative investigations and their 
results in the selection of adult patients for anti-reflux surgery. This approach combines the 
principles of evidence-based medicine, supported by systematic literature reviews and the 
use of a voting process. This method is an increasingly used in health care as a rigorous 
means of determining consensus for complex problems in medicine for which evidence from 
controlled trials is lacking.1,12–15 
 
The principal steps in the process were: 1) selection of an international Consensus Group 
consisting of several experts in GERD management with different clinical and scientific 
background to contribute to this expert panel; 2) development of draft statements by a 
Working Group composed of 5 Consensus Group experts with varied backgrounds; 3) 
systematic literature reviews to identify evidence to support each statement; 4) three 
rounds of repeated voting of the statements and voting discussion until a stable level of 
consensus voting was reached; and 5) grading of the strength using accepted criteria.16 
For the Consensus Group, which comprised the Working Group, 42 international experts 
with demonstrated knowledge/expertise were invited, and 35 from 15 countries (Australia, 
Belgium, Brazil, Canada, Denmark, France, Italy, Japan, Netherlands, Norway, Sweden, 
Switzerland, Turkey, UK and USA) agreed to participate. The group, consisting of 
gastroenterologists, surgeons and physiologists combined a diversity of views and expertise 
related to GERD diagnosis and management.  
 
We conducted a systematic literature search using a number of relevant keywords (MeSH: 
anti-reflux surgery and manometry / endoscopy / pH-metry / gastric emptying / 
comorbidities / barium X-ray). A core panel of 5 members reviewed the list of publications 
and identified the ones relevant to the process. These were stored in PDF format on a 
central server to which Delphi panel members had access. The references cited in this 
chapter are only a selection of the articles reviewed in each area and were selected to clarify 
the discussion.  
The Working Group developed an initial 27 statements and prepared and reviewed the 
evidence to support the statements that were presented to the Consensus Group. The 
Consensus Group subsequently revised, expanded and consolidated the statements, 
ultimately providing 37 statements to start the Delphi process. The experts were then 
allocated to groups of 4 and each member also functioned as lead expert for one statement. 
Each lead expert prepared a short summary of the available evidence (using the papers on 
the central server as literature source) for this statement, which was later further updated 
based on input from other members. Statements were revised by the Working Group based 
on the feedback from the Consensus Group before the start of the first voting round and 
based on additional literature reviews, but also after each voting round.  
 Three voting rounds followed where each statement was presented with the evidence 
summary, and then the entire panel indicated the degree of agreement for the statement 
using a 6-point Likert scale (Table 1). When 80% of the Consensus Group agreed (A+ or A) 
with a statement, this was defined as consensus. All votes were mutually anonymous. The 
strength of evidence for each statement was scored using the GRADE system (Table 2).17 All 
statements with grading and references are found in table 3. 
 
The following statements, on relevant aspects to consider adult patients for anti-reflux 
surgery, were composed by the Working Group and reviewed and adjusted as needed by the 
Consensus Group. All statements label patients with certain characteristics as “good 
candidates for anti-reflux surgery”.  This does not imply that surgery must be pursued in 
these patients, but it identifies them as potentially suitable for referral for surgery. 
Moreover, it is essential to understand that a decision for anti-reflux surgery based on a 
single characteristic (captured in a single statement) is also not appropriate. Referring a 
patient for anti-reflux surgery has to be an informed decision process, based on both 
positive and negative supporting findings.  
 
Results 
Clinical presentation and co-morbidities 
1. Patients with heartburn as the main symptom who respond satisfactorily to PPIs are good 
candidates for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 94.1%: A+ 67.6%, A 26.5%, A- 5.9%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE A 
 The vast majority of pre- and post-surgery studies in the literature enroll patients with 
‘typical’ GERD symptoms which include both heartburn and regurgitation, as well as GERD 
patients who have typical symptoms refractory to acid suppression therapy. Several peer-
reviewed studies investigating patients who reported a complete or partial response to PPI 
therapy prior to anti-reflux surgery, showed a benefit of anti-reflux surgery.18–21 Moreover, 
the response to PPI therapy, good compliance and objective preoperative evidence of acid 
reflux all predict a favorable outcome.22 However, specific data on heartburn as the main 
symptom pre-operatively and the response of heartburn symptoms to anti-reflux surgery 
were (often) not provided. 
There is also the issue of the terminology “satisfactorily”, which is very subjective. It has 
indeed been shown that responses to satisfactorily relief could possibly be influenced by 
baseline severity.23,24 However, this terminology is easy to understand by patients and it fits 
within the practice of medicine in the office setting. Furthermore, in IBS therapy trials, the 
usefulness of “satisfactorily relief” as an outcome parameter was linked to its ability to 
integrate various symptoms and the impact of therapy on various symptoms.25    
 
2. Patients with regurgitation as the main symptom are good candidates for anti-reflux 
surgery, regardless of the response pattern to PPI therapy. 
STATEMENT NOT ENDORSED, overall agreement 79.4%: A+ 14.7%, A 64.7%, A- 11.8%, D- 
5.9%, D 2.9%, D+ 0.0%.                
GRADE B 
 
The ability for PPIs to adequately improve regurgitation appears to be much less than their 
ability to improve heartburn.26,27  In the literature there is a lack of solid evidence to support 
the statement above. However, in a systematic analysis, surgery does appear to be superior 
to PPIs in alleviating symptomatic regurgitation, although dysphagia, rectal flatulence and 
the inability to belch or vomit were significantly more common in patients treated 
surgically.8,28,29 Important to notice is that symptoms of regurgitation due to primary 
esophageal motility disorders (e.g. achalasia, rumination syndrome) have to be ruled out by 
means of esophageal motility testing (preferably using high-resolution manometry (HRM)) 
before referring a patient for anti-reflux surgery.  
 
3. Patients with reflux-hypersensitive esophagus (normal acid exposure but positive 
symptom association with reflux events) are good candidates for anti-reflux surgery.   
STATEMENT NOT ENDORSED, overall agreement 55.9%: A+ 5.9%, A 50.0%, A- 26.5%, D- 
11.8%, D 2.9%, D+ 2.9%.                
GRADE C 
 
Reflux hypersensitivity is categorized as a functional disorder in the latest Rome IV criteria 
and defined as “patients with esophageal symptoms who lack evidence of reflux on 
endoscopy or abnormal acid burden on reflux monitoring, but show triggering of symptoms 
by physiologic reflux”.3 Symptoms in patients with reflux hypersensitivity are caused by 
reflux events (main difference with functional heartburn), therefore anti-reflux surgery can 
theoretically improve symptoms as it minimizes esophageal reflux. The majority of studies 
suggest that patients with a hypersensitive esophagus are possibly good candidates for anti-
reflux surgery 4,30-34, while a few reports suggest the opposite.35 More specifically, outcome 
in patients with hypersensitive esophagus where reflux has been documented in the past 
(either by the presence of esophagitis or a pathological acid exposure time) is similar as to 
patients with documented reflux without being hypersensitive.31,32 However, a recent study 
by Patel et al. showed that pure acid sensitivity was a negative predictor for symptom 
improvement with anti-reflux therapy, including surgical management.35 Moreover, patients 
with reflux hypersensitivity often display a high level of anxiety. Blondeau et al. 
demonstrated that psychosocial factors and somatization might contribute to symptom 
perception in patients with reflux hypersensitivity.36 This confounding factor has to be taken 
into consideration before referring these patients for anti-reflux surgery. 
 
4. Patients with functional heartburn (Rome III/IV criteria, who have no association of 
symptoms with documented episodes of reflux events) are poor candidates for surgery. 
STATEMENT ENDORSED, overall agreement 100%: A+ 91.2%, A 8.8%, A- 0.0%, D- 0.0%, D 
0.0%, D+ 0.0%.                 
GRADE B 
 
Functional heartburn is defined according to the Rome IV criteria as “a burning retrosternal 
discomfort or pain refractory to optimal anti-secretory therapy in the absence of gastro-
esophageal acid reflux, histopathologic mucosal abnormalities, major motor disorders, or 
structural explanations”.3 In other words, in functional heartburn, symptoms manifest 
themselves without association to reflux events. From the mechanistic point of view, it is 
therefore unlikely that functional heartburn would be improved by anti-reflux surgery. The 
few available studies do not support the efficacy of surgery.34,37 
 
5a. Patients with non-cardiac chest pain are good candidates for anti-reflux surgery only if 
symptoms can be attributed to reflux. 
STATEMENT NOT ENDORSED, overall agreement 79.4%: A+ 14.7%, A 64.7%, A- 14.7%, D- 
2.9%, D 2.9%, D+ 0.0%.                
GRADE C 
 
Non cardiac chest pain (NCCP) is a common condition, with a prevalence of up to 25% in the 
US adult population.38 After excluding a cardiac cause, reflux is the most common underlying 
mechanism for this disorder. Patients with NCCP might be referred to anti-reflux surgery 
after ruling out esophageal motility disorders such as hypercontractile esophagus and 
functional chest pain.39 Although literature on GERD-related NCCP as the sole indication for 
surgical treatment is non-existent, fundoplication has been performed in this patient group. 
Improvement after surgical treatment is better in patients with a clear correlation between 
reflux events and symptoms, in patients who also display typical reflux symptoms such as 
heartburn and thirdly when there is a satisfactory response to PPIs prior to the surgery.40–46  
 
5b. Patients with extra-esophageal syndromes (asthma, chronic cough or laryngitis) are good 
candidates for anti-reflux surgery only if symptoms can be attributed to reflux 
STATEMENT NOT ENDORSED, overall agreement 44.1%: A+ 8.8%, A 35.3%, A- 44.1%, D- 
8.8%, D 2.9%, D+ 0.0%.                
GRADE C 
 
The vast majority of data is reported in patients with typical GERD symptoms and co-existing 
extra-esophageal symptoms that seem to respond to surgery. Varying degrees of symptom 
improvement has been shown mainly in case series in respiratory symptoms, asthma, cough  
and laryngopharyngeal symptoms.47–71 Few data are available on the outcome of anti-reflux 
surgery for isolated atypical symptoms. Moreover, patient selection remains uncertain as 
there is no well-established method for demonstrating that these symptoms can be 
attributed to reflux. The use of symptom markers is valid for typical reflux symptoms, 
however in case of extra-esophageal symptoms it has been subject of debate for a long time. 
An objective monitoring for chronic cough can be added through ambulatory manometry or 
acoustic monitoring.72-75 Outcomes of Nissen fundoplication in patients with chronic cough 
attributable to reflux were good albeit in uncontrolled and often retrospective studies, but 
these were selected patients who also displayed a positive pH-monitoring.50–60,62-70 It has to 
be stressed out that none of the studies were placebo/sham controlled, which is pivotal in 
studying the exact effect of anti-reflux surgery in chronic cough patients. 
 
6. Patients with eosinophilic esophagitis (EoE) on esophageal biopsies are poor candidates 
for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 88.2%: A+ 61.8%, A 26.5%, A- 8.8%, D- 2.9%, D 
0.0%, D+ 0.0%.                GRADE C 
 
There is evidence in the literature that eosinophilic esophagitis in children and adults does 
not respond to anti-reflux surgery.76–79 Obtaining esophageal biopsies in all patients 
evaluated for Nissen fundoplication is debatable, as reports suggest a low prevalence of 
eosinophilic esophagitis in adults with refractory heartburn.80 
 
7. Patients with scleroderma (and/or other severe smooth muscle disease) are poor 
candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 64.7%: A+ 11.8%, A 52.9%, A- 26.5%, D- 
5.9%, D 2.9%, D+ 0.0%.                
GRADE C 
 
Data on the outcome of anti-reflux surgery in scleroderma patients (systemic sclerosis) is 
contradictory: there are a few non-randomized studies reporting (partial or full) resolution of 
reflux symptoms positive results of anti-reflux surgery, while other studies suggest that 
surgery is of limited success in these patients.81-86 Although the severity of reflux symptoms 
improved after Nissen fundoplication, post-operative dysphagia was present in 38-71% of 
scleroderma patients.81,83,87 A retrospective study suggested laparoscopic Roux-en-Y gastric 
bypass might be a better option in patients with systemic sclerosis-associated reflux: less 
dysphagia and improved reflux control was seen after Roux-en-Y gastric bypass compared to 
fundoplication.83,88 Although the esophagus is not always affected in patients with systemic 
sclerosis, the majority of patients with esophageal involvement is found to have aperistalsis, 
which is a risk factor for postoperative dysphagia also in non-scleroderma patients.89-91 
 
8. Patients with concomitant functional disorders such as dyspepsia and IBS are good 
candidates for anti-reflux surgery, only if symptoms can be attributed to reflux. 
STATEMENT NOT ENDORSED, overall agreement 64.7%: A+ 23.5%, A 41.2%, A- 26.5%, D- 
8.8%, D 0.0%, D+ 0.0%.                
GRADE B 
 
According to Rome IV criteria, functional dyspepsia (FD) is defined as “a medical condition 
that significantly impacts on the usual activities of a patient and is characterized by one of 
the following symptoms: postprandial fullness, early satiation, epigastric pain or epigastric 
burning that are unexplained after a routine clinical evaluation”.92 Within patients with FD, a 
distinction between postprandial distress syndrome (PDS), with predominant postprandial 
fullness and early satiation and epigastric pain syndrome (EPS) characterized by epigastric 
pain or epigastric burning is made. There are currently no data about the influence of Rome 
III/IV FD comorbidity on the outcome of anti-reflux surgery, but it may parallel the inferior 
response to PPIs.93 Studies suggest that anti-reflux surgery is not contraindicated in patients 
with dyspepsia comorbidity since these symptoms also tend to improve, but they do point 
out that the expected outcome is worse in patients with dyspepsia comorbidity.94  
IBS is defined in the Rome IV criteria as “recurrent abdominal pain associated with 
defecation or a change in bowel habits”. Disordered bowel habits are typically present (i.e. 
constipation, diarrhea, or a mix of constipation and diarrhea), as are symptoms of abdominal 
bloating/distention. Symptom onset should occur at least 6 months before diagnosis and 
symptoms should be present during the last 3 months.95 A study by Raftopoulos et al. 
demonstrated that preoperative IBS is not a contraindication of anti-reflux surgery.96 
Although Axelrod et al. do not state that IBS is a contraindication of anti-reflux surgery, they 
showed that patients with a diagnosis of functional bowel disease or with preoperative 
symptoms of functional bowel disease were more likely to have a poor outcome compared 
to patients without the diagnosis or symptoms of functional bowel disease.97 The reported 
data - although scarce and variable in quality - indicate that neither FD nor IBS comorbidity is 
a contraindication for anti-reflux surgery because of a similar improvement of typical reflux 
symptoms. However extensive counselling about the possibility of persistent functional GI 
symptoms and increased risk of gas-bloat syndrome postoperatively is warranted. 
 
9. Patients with a BMI>35 kg/m2 are poor candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 23.5%: A+ 2.9%, A 20.6%, A- 17.6%, D- 
14.7%, D 38.2%, D+ 5.9%.                
GRADE B 
 
Obesity has been implicated as a major and independent risk factor for GERD by several 
mechanisms (increase of the intra-gastric pressure and of the abdominal-thoracic pressure 
gradient, increased gastric peptic secretion, abnormal gastric emptying).98,99 Losing weight 
should be the first pillar in GERD treatment for obese patients. Although Perez et al. 
demonstrated that there was a 31% occurrence rate of GERD after anti-reflux surgery in 48 
obese patients, other more recent studies have shown that preoperative obesity was not 
associated with a poorer outcome following laparoscopic Nissen fundoplication.100–104  
 
10. Patients with psychiatric illness (major depression or anxiety disorder) are good 
candidates for anti-reflux surgery only if symptoms can be attributed to reflux. 
STATEMENT NOT ENDORSED, overall agreement 32.4%: A+ 2.9%, A 29.4%, A- 29.4%, D- 
20.6%, D 14.7%, D+ 2.9%.                
GRADE C 
 
Only few studies investigated the influence of psychiatric comorbidity on the outcome of 
anti-reflux surgery in GERD patients. It has been demonstrated that patients with GERD and 
concomitant psychiatric disorders (major depression or anxiety as defined by the DSM-IV) 
have more severe symptoms and lower quality of life at baseline. Even if a 24h pH-
monitoring is normal after surgery, these patients report less symptom relief and less quality 
of life improvement compared to patients without psychiatric comorbidity.105–108 
 
11. Patients known with substance abuse (such as alcohol abuse and drug abuse) are poor 
candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 26.5%: A+ 8.8%, A 17.6%, A- 50.0%, D- 
5.9%, D 17.6%, D+ 0.0%.                
GRADE D 
 
Alcohol and smoking may induce GER by decreasing lower esophageal sphincter (LES) 
pressure and disturbance of esophageal motility, although there is no evidence that lifestyle 
and dietary changes e.g. stopping smoking, will improve symptoms.99,109–112 Impaired 
swallow-induced LES relaxation and esophageal body dysmotility were observed both in 
healthy volunteers and in symptomatic patients with dysphagia receiving opioids.113,114  
Additionally, there is no evidence in the literature that all these factors may have an impact 
on the results of anti-reflux surgery.115,116 
 
12. Patients with dental erosions related to documented reflux are good candidates for anti-
reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 44.1%: A+ 0.0%, A 44.1%, A- 29.4%, D- 
8.8%, D 5.9%, D+ 11.8%.                
GRADE D 
 The literature on dental erosions related to GERD is limited. Most studies indicate an 
increased prevalence of dental erosions in patients with GERD.117 On average, 17 to 68% 
with GERD have dental erosions.118–124 A study by Wilder-Smith et al. showed that 
esomeprazole 20mg b.i.d. significantly reduced the decrease in enamel thickness compared 
to placebo, suggesting that treatment of GERD may reduce the development of dental 
erosions.121 In a 1-year follow-up study, the same group described no further progression in 
erosive tooth wear in 74% of the patients.125 However, to date there are no studies available 
evaluating the effect of anti-reflux surgery on dental erosions. 
 
Esophagogastroduodenoscopy 
13. Endoscopy is mandatory and has to be carried out in the last year prior to anti-reflux 
surgery. 
STATEMENT ENDORSED, overall agreement 94.1%: A+ 82.4%, A 11.8%, A- 5.9%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE B 
 
The literature on the use of and diagnostic output from endoscopy in the preoperative work-
up of GERD patients before anti-reflux surgery is very extensive. Although there is no solid 
evidence that endoscopy is mandatory prior to anti-reflux surgery, there seems to be a 
general consensus that endoscopy shall be performed before anti-reflux surgery. The proper 
timing for endoscopy has not been studied so far and is therefore not well-defined and the 
voting outcome reflects the opinion and clinical experience of the experts of the panel. 
 
14. There is no need to wean the patient off PPI for an endoscopy in the preoperative work-
up for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 88.2%: A+ 41.2%, A 47.1%, A- 2.9%, D- 5.9%, D 
0.0%, D+ 2.9%.                GRADE C 
 
The literature to support a decision on whether there is greater value of maintaining or for 
stopping PPI therapy before making a decision regarding selection of a patient for anti-reflux 
surgery is scarce. Standard current practice seems to either perform endoscopy on PPI or not 
to specify.28,126,127 The information gained by pre-operative endoscopy relates to the need to 
assess and grade dysplasia in Barrett's esophagus, identify the possibility of a short 
esophagus and assess the size and configuration of hiatal hernia (HH).128,129 As interrupting 
PPI therapy for these assessments is unnecessary and unhelpful, patients can therefore 
continue their PPI treatment regimen for endoscopic assessment of reflux prior to a decision 
regarding the potential value of anti-reflux surgery. 
 
15. Patients with GERD symptoms and an endoscopic diagnosis of a HH are good candidates 
for anti-reflux surgery.  
STATEMENT ENDORSED, overall agreement 82.4%: A+ 20.6%, A 61.8%, A- 14.7%, D- 2.9%, D 
0.0%, D+ 0.0%.                GRADE B 
 
A HH disrupts the anatomy and physiology of the normal anti-reflux mechanism (reducing 
the LES-length and LES-pressure, impairing augmentation of the LES by the right crus, 
impairing esophageal peristalsis, increasing cross-sectional area of the esophago-gastric 
junction (EGJ)). The herniated stomach acts as a reservoir allowing reflux into the lower 
esophagus during swallowing. The presence of a HH is associated with increased symptoms 
of reflux, increased prevalence and severity of reflux esophagitis, Barrett’s esophagus, 
esophageal adenocarcinoma and reduced efficacy of PPI.130,131 The severity of esophagitis is 
best predicted by size of HH, followed by LES pressure, in that order.132 Although patients 
with a large HH are more prone to have pathological reflux and more symptoms, not all 
patients with a HH have GERD.133  
Up to date, there are no prospective studies reporting the influence of HH in recommending 
anti-reflux surgery. The Canadian Consensus Conference on the management of GERD in 
adults did suggest that a significant HH, because of its likely contribution to reflux in an 
individual patient, may tip the balance towards surgery.134 Most series looking for 
independent predictors of success for anti-reflux surgery did not find presence of HH to be 
significant in multivariate analysis.10,135 
 
16a. Patients with GERD symptoms and unequivocal presence of reflux esophagitis LA grade 
A or higher off PPI are good candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 50.0%: A+ 17.6%, A 32.4%, A- 47.1%, D- 
2.9%, D 0.0%, D+ 0.0%.                
GRADE B 
 
16b. Patients with GERD symptoms and unequivocal presence of reflux esophagitis LA grade 
B or higher off PPI are good candidates for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 91.2%: A+ 47.1%, A 44.1%, A- 8.8%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE B 
 
GERD patients can be subdivided into those with erosive reflux disease (ERD, presence of 
mucosal breaks) and those with non-erosive reflux disease (NERD, absence of mucosal 
breaks) based on upper gastrointestinal endoscopy findings.136 It has been demonstrated 
that progression from NERD to erosive esophagitis occurs while regression from ERD to 
NERD is rare.137,138 The diminished response to medical treatment in NERD patients would 
support a greater role for surgery in NERD than in ERD. It has been demonstrated that 
subjective and objective long-term outcomes of Nissen fundoplication were similar in ERD 
and NERD, and results were sustained for up to 5 years after surgery.139 Moreover, in terms 
of symptoms and signs of erosive esophagitis a long-term study reported that surgery was 
superior to conservative management with modified lifestyle and medication.138 
Historically, reflux esophagitis off PPI was considered a good selection criterion, usually in 
combination with abnormal pH-metry, for patient selection for an anti-reflux surgery. Active 
esophagitis is a definite sign of ongoing pathological reflux and may help to select patients 
for surgery. More than 85% of the patients with documented esophagitis were satisfied with 
the results of surgery (laparoscopic or open).140 However, previous studies demonstrated 
that up till 15 % of the general population have esophagitis LA grade A or higher. Almost half 
of these patients, in particular those with LA grade A are asymptomatic.2,141 
Patient selection though remains mostly based on symptoms, as indicated by the recent 
LOTUS trial.8,142  
 
17. Patients with GERD symptoms without reflux esophagitis during endoscopy performed 
off PPIs are poor candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 2.9%: A+ 0.0%, A 2.9%, A- 2.9%, D- 23.5%, D 
44.1%, D+ 26.5%. 
 The diagnosis of NERD is based on upper gastrointestinal endoscopy findings and a positive 
pH or pH-impedance study.3,136  Impairment of quality of life however and severity of 
symptoms are similar as for ERD.143,144  In theory, the diminished response to medical 
treatment in NERD patients could support a greater role for surgery in NERD than in ERD. 
When comparing long-term outcome results of anti-reflux surgery in PPI-refractory NERD 
and ERD patients, it was demonstrated that both subjective and objective long-term 
outcomes were similar in ERD and NERD, and results were sustained for up to 5 years after 
surgery.32,145 
 
18. Patients with GERD symptoms and Barrett’s esophagus (non-dysplastic specialized 
intestinal metaplasia) on biopsies of the distal esophagus are good candidates for anti-reflux 
surgery. 
STATEMENT ENDORSED, overall agreement 82.4%: A+ 17.6%, A 64.7%, A- 14.7%, D- 2.9%, D 
0.0%, D+ 0.0%.                GRADE B 
 
The presence of Barrett’s esophagus can be considered proof of the presence of GERD. 
Many studies confirm that anti-reflux procedures in patients with Barrett’s esophagus 
effectively reduce reflux-related symptoms and that uncomplicated Barrett’s esophagus 
does not influence outcome of anti-reflux surgery.22,146-155 A meta-analysis found no 
evidence that anti-reflux surgery prevents the progression to carcinoma of the esophagus, 
therefore post-operative endoscopic follow-up should be maintained.156 In patients with 
refractory GERD eligible for anti-reflux surgery the presence of Barrett’s esophagus should 
not be a contra-indication. On the other hand, anti-reflux surgery should not be suggested to 
asymptomatic patients with Barrett’s esophagus or to patients with short segment Barrett’s 
esophagus to prevent evolution to dysplasia or adenocarcinoma. 
 
19. In patients considered for anti-reflux surgery, biopsies of the esophageal body should be 
obtained during endoscopy. 
STATEMENT NOT ENDORSED, overall agreement 73.5%: A+ 58.8%, A 14.7%, A- 11.8%, D- 
2.9%, D 2.9%, D+ 8.8%.                
GRADE C 
 
EoE and GERD are distinct clinical entities, theoretically with different pathophysiology and 
treatment. However, their differentiation may sometimes be problematic and disease 
previously thought to be associated with GERD may really be manifestations of EoE.157,158 
Additionally, there may be a benefit of treatment of GERD in EoE, particularly in pediatric 
patients.159,160 Further confounding this issue of distinction is that patients not suspected of 
having EoE (those not undergoing preoperative biopsy) who receive anti-reflux surgery, have 
been reported to have poor outcomes.77,79 The finding of eosinophils on biopsy does not 
necessarily confirm the diagnosis of EoE or exclude other esophageal diseases, therefore 
rendering the need for mandatory biopsies questionable.161,162 It has been shown that cost-
benefit is only present when the prevalence of abnormal findings is expected to be 8% or more.163 
 
Barium swallow 
20. In patients with suspicion of HH or short esophagus a barium swallow is mandatory in 
the preoperative work-up for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 88.2%: A+ 44.1%, A 44.1%, A- 5.9%, D- 2.9%, D 
2.9%, D+ 0.0%.                GRADE B 
 
It is commonly accepted that 2.5 cm of intra-abdominal esophagus is necessary to perform 
an effective anti-reflux procedure. Today, most anti-reflux operations are performed 
laparoscopically. The pneumoperitoneum necessary to perform laparoscopy elevates the 
diaphragm into the mediastinum and appears to “lengthen” the esophagus. Failure to 
recognize that the esophagus is shortened may result in an inadequate length of intra-
abdominal esophagus at surgery. If a HH repair is constructed under tension on a short 
esophagus, the hernia is reduced below the diaphragm at surgery and then retracts into the 
chest over time. The fundoplication may or may not remain subdiaphragmatically or it may 
disrupt or “slip” onto the stomach. Slipped Nissen fundoplications may therefore result from 
the failure to recognize a shortened esophagus before surgery. The occurrence of the true 
short esophagus is indeed thought to be responsible for 20% to 33% of the surgical failures 
after open or laparoscopic fundoplication.164 A study by Mattioli et al. demonstrated that 
short esophagus is present in about 20% of patients undergoing routine anti-reflux surgery, 
highlighting the importance of performing adequate testing.165  
If the hernia is identified in the upright position, it is assumed that there is esophageal 
shortening. In addition, the esophagus is probably shortened when the HH length is 5 cm or 
greater alone or in combination with a stricture or a long-segment (> 3 cm) Barrett’s 
esophagus.164,166 Other radiological findings that suggest a short esophagus include severe 
extensive ulcerative esophagitis, straightening or loss of the angle of His, the presence of a 
stricture alone, and type III mixed or complex para-esophageal hernias.167  
In summary, if endoscopy reveals the presence of a large hernia and/or the presence of 
severe esophagitis or long segment Barrett’s esophagus, a barium swallow performed by a 
dedicated upper GI radiologist is strongly recommended before surgical intervention. This 
will allow to better plan the technical details of the surgery in order to eventually reduce the 
risk of anatomical and/or symptomatic recurrence.168,169 
 
21. Patients with GERD symptoms and a small or medium size sliding HH on barium swallow 
are good candidates for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 82.4%: A+ 20.6%, A 61.8%, A- 8.8%, D- 8.8%, D 
0.0%, D+ 0.0%.                GRADE B 
 
Very few studies have examined the effect of a HH on the outcome of anti-reflux surgery. A 
study by Power et al. defined a hiatal hernia size >3 cm at time of the surgery as a predictor 
of failure.135 However, the presence and the size of a HH had no relationship with outcome 
according to several other studies.170–173  
 
22. Patients with GERD symptoms and a large sliding HH on barium swallow are good 
candidates for anti-reflux surgery in the absence of short esophagus. 
STATEMENT ENDORSED, overall agreement 85.3%: A+ 50%, A 35.3%, A- 8.8%, D- 2.9%, D 
0.0%, D+ 2.9%.                 
GRADE B 
 
Upper endoscopy and barium swallow are commonly used to diagnose short sliding HH. It 
has been demonstrated, that in morbidly obese patients, barium swallow is superior to 
endoscopy in diagnosing sliding HH.174 Preoperative barium swallow can reveal more details 
on the sliding hiatal hernia and contribute to better tailoring the anti-reflux surgery.168 
Although there is currently no consensus on the definition for small, medium and large HH, 
often the cutoff of >3cm or hernias belonging to category II till IV have been used to define a 
large hiatal hernia.94,175,176 As 2.5 cm of intra-abdominal esophagus is mandatory to offer 
effective anti-reflux surgery, in large sliding HHs (larger intra-thoracic component), a more 
comprehensive dissection is needed.164  
 
23. Symptomatic patients with a para-esophageal hernia on barium swallow are good 
candidates for anti-reflux surgery in addition to para-esophageal hernia repair. 
STATEMENT ENDORSED, overall agreement 97.1%: A+ 44.1%, A 52.9%, A- 2.9%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE C 
 
Para-esophageal hernias (PEH) are subtypes of HH, defined as a herniation of the peritoneal 
cavity into the chest through the diaphragmatic hiatus. 
Given the difficulty of distinguishing if reflux symptoms are from PEH alone or independent 
of the PEH, most surgeons routinely add an anti-reflux procedure (fundoplication) after PEH 
repair in elective situations.177 A recent pilot trial by Muller-Stich et al, showed a lesser 
degree of reflux and a less esophagitis in patients where a fundoplication was added to the 
PEH repair compared to those with a PEH repair only.178  
Some authors advocate a selective approach to anti-reflux procedures, with pre-operative 
testing (including manometry, pH-metry, or endoscopy) and patient symptoms determining 
whether or not to add a fundoplication.179 Others suggest always performing an anti-reflux 
procedure, but tailoring the type of fundoplication (e.g. full or partial) depending on the 
patient.180 A minority suggest that fundoplication should be avoided due to the increased 
risk of dysphagia with anti-reflux procedures after PEH repair.181 None of these approaches 
however have been proven superior to others in a prospective trial. 
 
24. Patients with GERD symptoms and a short esophagus on barium swallow are poor 
candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 17.6%: A+ 2.9%, A 14.7%, A- 23.5%, D- 
41.2%, D 11.8%, D+ 5.9%.                
GRADE C 
 
In the absence of adequate comparative studies, the question of the short esophagus 
remains controversial, and there is insufficient evidence to preclude patients with 
radiological suspicion of a short esophagus from anti-reflux surgery. If patients progress to 
surgery, there is also insufficient evidence to define the best surgical procedure in this 
scenario. Well-designed case-control or randomized clinical trials are needed to provide an 
evidence base to address this question. 
 
Esophageal manometry 
25. Esophageal manometry is mandatory to select patients for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 94.1%: A+ 82.4%, A 11.8%, A- 5.9%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE D 
 
Esophageal manometry should be performed prior to anti-reflux surgery to rule out a major 
motor disorder, such as achalasia, EGJ outflow obstruction or absent contractility.182,183 
There is no data to support that the manometric finding of distal esophageal spasm (DES), 
Jackhammer esophagus or minor disorders of peristalsis, such as fragmented peristalsis 
predicts post-operative dysphagia. Incorporating HRM and impedance into pressure flow 
parameters might be helpful in predicting outcome since the dysphagia risk index appeared 
to be helpful in identifying patients at risk for post-fundoplication dysphagia.184  
 
26. Patients with GERD symptoms and a hypercontractile esophagus (Jackhammer and the 
previously described Nutcracker) esophagus on manometry are good candidates for anti-
reflux surgery if symptoms can be attributed to reflux.  
STATEMENT NOT ENDORSED, overall agreement 64.7%: A+ 11.8%, A 52.9%, A- 29.4%, D- 
2.9%, D 2.9%, D+ 0.0%.                
GRADE D 
 
Data on outcome of anti-reflux surgery of patients with a hypercontractile esophagus is 
scarce: there are no randomized, controlled trials available in literature. However, 
retrospective data on outcome of patients with nutcracker esophagus (although no longer 
defined in the Chicago classification v3.0) undergoing anti-reflux surgery show no difference 
compared to patients with a normal esophageal motility pattern.185 Manometric 
abnormalities after a Nissen fundoplication were even improved in 2 patients with a 
Jackhammer esophagus.186 Hypertensive esophageal contraction patterns are not a 
contraindication for anti-reflux surgery however, patients and clinicians should be aware of 
the risk of developing chest pain after the surgery.187 
 
27. Patients with GERD symptoms and distal esophageal spasm on manometry are poor 
candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 64.7%: A+ 26.5%, A 38.2%, A- 20.6%, D- 
11.8%, D 0.0%, D+ 0.0%.               GRADE D 
 
Patients with DES are poor candidates for anti-reflux surgery, provided that the motor 
disorder has been well characterized, preferably using HRM. Therapeutic approaches 
indicated for patients with DES include medicines such as sildenafil, as well as endoscopic 
injection of botulin toxin and surgical myotomy.188–190 Although some patients may benefit 
from acid suppressive therapy, anti-reflux surgery as the unique treatment should be 
avoided in patients with DES. 
 
28. In patients with GERD symptoms and hypocontractility of the esophageal body on 
manometry, anti-reflux surgery should be tailored.  
STATEMENT NOT ENDORSED, overall agreement 47.1%: A+ 5.9%, A 41.2%, A- 41.2%, D- 
0.0%, D 5.9%, D+ 5.9%.                
GRADE D 
 
There are no good data to suggest tailoring of anti-reflux surgery to esophageal body 
hypomotility or hypocontractility.191,192 Provocative manoeuvres during manometry could in 
the future identify patients where peristaltic performance following fundoplication can 
modify the risk for postoperative dysphagia. Multiple rapid swallows (MRS) are often added 
to the manometric protocol as a marker for esophageal body peristaltic reserve. It has been 
shown that MRS testing before laparoscopic anti-reflux surgery is able to help predict late 
postoperative dysphagia.193,194 
 
29. Patients with GERD symptoms and severe hypocontractility or failed peristalsis on 
manometry are poor candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 64.7%: A+ 8.8%, A 55.9%, A- 23.5%, D- 
2.9%, D 8.8%, D+ 0.0%.                
GRADE D 
 
Hypocontractility is not a contraindication for anti-reflux surgery, since surgery more often 
than not improved these manometric abnormalities.191 Further research is warranted since 
very little data exists on outcome of patients with the most severe hypocontractility or 
aperistalsis. Similar as described above (statement 28) is the importance of adding MRS 
during a manometric protocol, which is a marker of contractile reserve of the 
esophagus.193,194 In addition, anti-reflux surgery can be tailored to each individual patient.  
It has to be repeated that the main indication for manometry in GERD patients considered 
for anti-reflux surgery is to identify patients with aperistalsis due to achalasia, who are 
candidates for fundoplication only when combined with myotomy of the LES. 
 
Reflux monitoring 
30. Esophageal pH (+/- impedance) monitoring off therapy is mandatory to select NERD 
patients for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 97.1%: A+ 91.2%, A 5.9%, A- 0.0%, D- 2.9%, D 
0.0%, D+ 0.0%.                GRADE B 
 In the absence of esophagitis (i.e. presence of mucosal breaks), pathological GER and/or 
positive reflux symptom association "off" therapy should be documented before embarking 
to anti-reflux surgery.22,33,195-198 In the preoperative setting, the added value of impedance in 
patients "off" therapy remains to be determined.  
Data on preoperative assessment “on” PPIs are scarce. Few uncontrolled and short studies 
suggest that good postoperative outcomes can be achieved in patients who are refractory to 
PPIs in whom pH-impedance monitoring demonstrated either an abnormal number of reflux 
episodes or positive symptom association analysis.33,199 
 
31. Esophageal pH (+/- impedance) monitoring off therapy should be performed for 
selection for anti-reflux surgery of patients who have short Barrett’s esophagus in the 
absence of erosive esophagitis. 
STATEMENT ENDORSED, overall agreement 88.2%: A+ 41.2%, A 47.1%, A- 5.9%, D- 0.0%, D 
5.9%, D+ 0.0%.                GRADE B 
 
Esophageal (impedance-) pH-monitoring off therapy should be performed in patients with 
short segment Barrett’s esophagus as it provides an objective quantification of patient’s 
GER.195 This evaluation off PPI therapy would provide a baseline comparator in assessing the 
efficacy of acid suppressive and/or reflux reducing therapies.  
 
32. Patients with GERD symptoms and normal reflux exposure on pH (+/- impedance) 
monitoring off PPI therapy are poor candidates for anti-reflux surgery. 
STATEMENT ENDORSED, overall agreement 82.4%: A+ 17.6%, A 64.7%, A- 17.6%, D- 0.0%, D 
0.0%, D+ 0.0%.                GRADE B 
 
There is very limited data examining the outcomes of surgery in patients with normal reflux 
monitoring. This is in large part due to the fact that most of the studies evaluating outcomes 
of anti-reflux surgery require abnormal reflux monitoring as a criteria to be eligible for 
surgery.57 Based upon the available evidence, it would appear that patients with normal 
reflux exposure on pH (+/- impedance) monitoring off therapy are indeed poor candidates 
for anti-reflux surgery. 
 
33a. Patients with GERD symptoms, a normal reflux exposure on pH (+/- impedance) 
monitoring off therapy and a positive symptom association are good candidates for anti-
reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 58.8%: A+ 14.7%, A 44.1%, A- 23.5%, D- 
17.6%, D 0.0%, D+ 0.0%. 
 
33b. Patients with GERD symptoms, a normal reflux exposure on pH (+/- impedance) 
monitoring off therapy and a positive reflux symptom association are good candidates for 
anti-reflux surgery, only if symptoms respond to PPI therapy. 
STATEMENT NOT ENDORSED, overall agreement 73.5%: A+ 11.8%, A 61.8%, A- 14.7%, D- 
5.9%, D 5.9%, D+ 0.0%. 
 
There is very limited data examining the outcomes of surgery in patients with normal reflux 
monitoring. This is in large part due to the fact that most of the studies evaluating outcomes 
of anti-reflux surgery require abnormal reflux monitoring as a criteria to be eligible for 
surgery.57 Some studies do suggest that reflux-hypersensitive patients with typical symptoms 
and an unsatisfactory response to PPIs may benefit from anti-reflux surgery with an outcome 
similar to the one of patients with pathological reflux.31,200 However, as mentioned above 
(statement 3) a recent study by Patel et al. showed that pure acid sensitivity was a negative 
predictor for symptom improvement with anti-reflux therapy, including surgical 
management.35 Results should therefore be interpreted with caution. 
 
34a. Patients with GERD symptoms and pathologic reflux exposure on pH (+/- impedance) 
monitoring off therapy and a negative reflux symptom association are eligible for anti-reflux 
surgery. 
STATEMENT NOT ENDORSED, overall agreement 58.8%: A+ 5.9%, A 52.9%, A- 29.4%, D- 
8.8%, D 2.9%, D+ 0.0%. 
 
34b. Patients with GERD symptoms and pathologic reflux exposure on pH (+/- impedance) 
monitoring off therapy and a negative reflux symptom association are eligible for anti-reflux 
surgery, only if symptoms respond to PPI therapy. 
STATEMENT NOT ENDORSED, overall agreement 66.7%: A+ 6.1%, A 60.6%, A- 9.1%, D- 6.1%, 
D 18.2%, D+ 0.0%. 
 
The literature available suggests that patients with proven pathological acid exposure who 
do not experience symptoms during pH (+/- impedance) monitoring or presenting a negative 
symptom-reflux association may still obtain good results from anti-reflux surgery.33,197 
Moreover, there is a subgroup of patients that is truly refractory to PPIs, with ongoing acid 
secretion.198  
 
35. Patients with pathologic reflux exposure on pH (+/- impedance) monitoring on PPI who 
respond to baclofen therapy are good candidates for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 20.6%: A+ 5.9%, A 14.7%, A- 61.8%, D- 
2.9%, D 11.8%, D+ 2.9%. 
 
Baclofen, a GABA B-agonist, is known to reduce the number of transient LES relaxations and 
subsequently, it reduces all types of reflux, including weakly acidic reflux.201 To date, there 
are no studies comparing baclofen with anti-reflux surgery, therefore it would be too 
speculative to say that patients responding to baclofen are good candidates for anti-reflux 
surgery. In the very recently published pediatric GER clinical guidelines, the use of baclofen 
prior to anti-reflux surgery can be considered in children in whom other pharmacological 
treatments have failed (weak recommendation).202  
 
Gastric emptying 
36. A gastric emptying test for solid food is necessary to select GERD patients with 
concomitant dyspeptic symptoms for anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 5.9%: A+ 2.9%, A 2.9%, A- 8.8%, D- 5.9%, D 
67.6%, D+ 11.8%. 
 
Studies performed to assess the role of a preoperative gastric emptying test in anti-reflux 
surgery have generated controversial results: some studies have shown that this evaluation 
is useful to select the best type of surgery and to avoid surgical failures, while others have 
denied the validity of such an approach.203–205 However, so far no study has been performed 
to establish whether the assessment of gastric emptying is relevant or not to favor success of 
surgery in GERD patients with concomitant dyspepsia symptoms. 
 
37. If the gastric emptying test is abnormal for solid food, patients should not undergo an 
anti-reflux surgery. 
STATEMENT NOT ENDORSED, overall agreement 2.9%: A+ 0.0%, A 2.9%, A- 0.0%, D- 20.6%, D 
67.6%, D+ 8.8%. 
 
Literature shows that there is no evidence to suggest that preoperative slow gastric 
emptying for solids is associated with a poor outcome after surgery with regard to reflux 
parameters.206,207 A study by Lundell et al. suggests that a slow preoperative gastric 
emptying for solids is weakly associated with symptoms of bloating.207 However, two other 
studies investigating the relationship between gastric emptying rates before and outcome 
after anti-reflux surgery could not confirm this.203,204 There is insufficient evidence to 
support the statement. 
 
Recommendations  
Based on the statements that generated consensus a number of recommendations can be 
made for selecting patients for anti-reflux surgery. These are summarized in Table 4.  
 
The Delphi process also identified several areas of uncertainty, requiring further research. It 
is unclear whether patients with regurgitation as a main symptom, patients with non-cardic 
chest pain, patients with extra-esophageal manifestations of reflux and patients with dental 
erosions are good candidates for anti-reflux surgery (statements 2,5,12). There is a lack of 
prospective controlled trials to support these statements. Patients with reflux 
hypersensitivity, patients with concomitant FD and IBS, and patients with major psychiatric 
co-morbidity are not considered good candidates for anti-reflux surgery (statements 3,8,10). 
There is a need for additional markers of beneficial outcome of anti-reflux surgery in these 
patients, given the frequent overlap of GERD with FD and IBS symptoms. There is no 
consensus that patients with scleroderma are poor candidates for anti-reflux surgery 
(statement 7). It is unclear to which extent patients with Jackhammer (or Nutcracker) 
esophagus or spasm on manometry are eligible for anti-reflux surgery (statements 26,27). 
The impact of esophageal hypocontractility on the eligibility or type of anti-reflux surgery is 
unclear (statements 28,29). It is unclear whether patients with reflux hypersensitivity are 
eligible for anti-reflux surgery (statement 33). Finally, it is unclear whether patients with 
pathological reflux monitoring but negative symptom association are good candidates for 
anti-reflux surgery (statement 34). 
It is important to stress that the decision of referring a patient for anti-reflux surgery has to 
take into account all positive as well as all negative support findings. Selecting patients 
suitable for anti-reflux surgery cannot be captured by one single statement and remains 
subject to guided clinical judgement and patient preference.  
 
Conclusion 
GERD, often accompanied by the typical reflux symptoms heartburn and regurgitation or by 
atypical reflux symptoms such as chronic cough and wheezing, is very common in the 
Western World.1,2 The first line treatment for GERD is acid suppressive therapy, most often 
by PPI intake. PPIs have shown to be very effective in healing esophagitis, however up to 
40% of GERD patients remain symptomatic while on an adequate dose of PPIs.5,6 Anti-reflux 
surgery is often recommended for patients with insufficient relief of symptoms during PPI 
intake, in case of intolerance to or anticipated long-term use of PPIs. However, to date, 
consensus guidelines defining clinical criteria and additional technical examinations that 
need to be performed for patient selection for anti-reflux surgery are lacking. Therefore, we 
aimed to develop the ICARUS guidelines using a Delphi process.  
 
The Consensus Group defined several statements that may guide clinicians and surgeons in 
their decision to select patients for anti-reflux surgery. All patients require endoscopy, pH-
monitoring off PPI and esophageal manometry. The consensus process also identified areas 
of uncertainty and some patient groups in whom referral for surgery should be avoided, 
such as functional heartburn.   
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Tables and Figures 
 
Table 1: 6-point Likert scale. 
point description 
A+ agree strongly 
A  agree with minor reservation 
A- agree with major reservation 
D- disagree with major reservation 
D  disagree with minor reservation 
D+ disagree strongly 
 
  
Table 2: Grading of recommendations assessment, development and evaluation system 16 
Code Quality of evidence Definition  
A High Further research is very unlikely to change our 
confidence in the estimate of effect 
 Several high-quality studies with consistent results 
 In special cases: one large, high-quality multicenter 
trial 
B Moderate Further research is likely to have an important impact on 
our confidence in the estimate of effect and may change 
the estimate. 
 One high-quality study 
 Several studies with some limitations 
C Low Further research is very likely to have an important 
impact on our confidence in the estimate of effect and is 
likely to change the estimate. 
 One or more studies with severe limitations 
D Very low Any estimate of effect is very uncertain. 
 Expert opinion 
 No direct research evidence 
 One or more studies with very severe limitations 
 
  
Table 3: All statements with grading and references.  
Statement Grade of 
Evidence 
References  
1. Patients with heartburn as the main symptom who respond 
satisfactorily to PPIs are good candidates for anti-reflux surgery. 
A 18-25 
2. Patients with regurgitation as the main symptom are good 
candidates for anti-reflux surgery, regardless of the response pattern 
to PPI therapy. 
B 8,26-29 
3. Patients with reflux-hypersensitive esophagus (normal acid 
exposure but positive symptom association with reflux events) are 
good candidates for anti-reflux surgery.   
C 3,4,30-36 
4. Patients with functional heartburn (Rome III/IV criteria, who have 
no association of symptoms with documented episodes of reflux 
events) are poor candidates for surgery. 
B 3,34,37 
5a. Patients with non-cardiac chest pain are good candidates for anti-
reflux surgery only if symptoms can be attributed to reflux. 
5b. Patients with extra-esophageal syndromes (asthma, chronic cough 
or laryngitis) are good candidates for anti-reflux surgery only if 
symptoms can be attributed to reflux. 
C 
 
C 
38-46 
 
47-75 
6. Patients with eosinophilic esophagitis (EoE) on esophageal biopsies 
are poor candidates for anti-reflux surgery. 
C 76-80 
7. Patients with scleroderma (and/or other severe smooth muscle 
disease) are poor candidates for anti-reflux surgery. 
C 81-91 
8. Patients with concomitant functional disorders such as dyspepsia 
and IBS are good candidates for anti-reflux surgery, only if symptoms 
can be attributed to reflux. 
B 92-97 
9. Patients with a BMI>35 kg/m2 are poor candidates for anti-reflux 
surgery. 
B 98-104 
10. Patients with psychiatric illness (major depression or anxiety 
disorder) are good candidates for anti-reflux surgery only if symptoms 
can be attributed to reflux. 
C 105-108 
11. Patients known with substance abuse (such as alcohol abuse and 
drug abuse) are poor candidates for anti-reflux surgery. 
D 99,109-116 
12. Patients with dental erosions related to documented reflux are D 117-125 
good candidates for anti-reflux surgery. 
13. Endoscopy is mandatory and has to be carried out in the last year 
prior to anti-reflux surgery. 
B 8,28,127 
14. There is no need to wean the patient off PPI for an endoscopy in 
the preoperative work-up for anti-reflux surgery. 
C 28,126-129 
15. Patients with GERD symptoms and an endoscopic diagnosis of a 
hiatal hernia (HH) are good candidates for anti-reflux surgery.  
B 10,130-135 
16a. Patients with GERD symptoms and unequivocal presence of 
reflux esophagitis LA grade A or higher off PPI are good candidates for 
anti-reflux surgery. 
16b. Patients with GERD symptoms and unequivocal presence of 
reflux esophagitis LA grade B or higher off PPI are good candidates for 
anti-reflux surgery. 
B 
 
 
B 
2,8,136-
141 
17. Patients with GERD symptoms without reflux esophagitis during 
endoscopy performed off PPIs are poor candidates for anti-reflux 
surgery. 
B 3,32,136,14
3-145 
18. Patients with GERD symptoms and Barrett’s esophagus (non-
dysplastic specialized intestinal metaplasia) on biopsies of the distal 
esophagus are good candidates for anti-reflux surgery. 
B 22,146-156 
19. In patients considered for anti-reflux surgery, biopsies of the 
esophageal body should be obtained during endoscopy. 
C 77,79,157-
163 
20. In patients with suspicion of HH or short esophagus a barium 
swallow is mandatory in the preoperative work-up for anti-reflux 
surgery. 
B 164-169 
21. Patients with GERD symptoms and a small or medium size sliding 
HH on barium swallow are good candidates for anti-reflux surgery. 
B 135,170-
173 
22. Patients with GERD symptoms and a large sliding HH on barium 
swallow are good candidates for anti-reflux surgery in the absence of 
short esophagus. 
B 94,164,168,
174-176 
23. Symptomatic patients with a para-esophageal hernia on barium 
swallow are good candidates for anti-reflux surgery in addition to 
para-esophageal hernia repair. 
C 177-181 
24. Patients with GERD symptoms and a short esophagus on barium 
swallow are poor candidates for anti-reflux surgery. 
C 164,166, 
167 
25. Esophageal manometry is mandatory to select patients for anti-
reflux surgery. 
D 182-184 
26. Patients with GERD symptoms and a hypercontractile esophagus 
(Jackhammer and the previously described Nutcracker) esophagus on 
manometry are good candidates for anti-reflux surgery if symptoms 
can be attributed to reflux.  
D 185-187 
27. Patients with GERD symptoms and distal esophageal spasm on 
manometry are poor candidates for anti-reflux surgery. 
D 188-190 
28. In patients with GERD symptoms and hypocontractility of the 
esophageal body on manometry, anti-reflux surgery should be 
tailored.  
D 191-194 
29. Patients with GERD symptoms and severe hypocontractility or 
failed peristalsis on manometry are poor candidates for anti-reflux 
surgery. 
D 191,193,19
4 
30. Esophageal pH (+/- impedance) monitoring off therapy is 
mandatory to select NERD patients for anti-reflux surgery. 
B 22,33,195-
199 
31. Esophageal pH (+/- impedance) monitoring off therapy should be 
performed for selection for anti-reflux surgery of patients who have 
short Barrett’s esophagus in the absence of erosive esophagitis. 
B 195 
32. Patients with GERD symptoms and normal reflux exposure on pH 
(+/- impedance) monitoring off PPI therapy are poor candidates for 
anti-reflux surgery. 
B 57 
33a. Patients with GERD symptoms, a normal reflux exposure on pH 
(+/- impedance) monitoring off therapy and a positive symptom 
association are good candidates for anti-reflux surgery. 
33b. Patients with GERD symptoms, a normal reflux exposure on pH 
(+/- impedance) monitoring off therapy and a positive reflux symptom 
association are good candidates for anti-reflux surgery, only if 
symptoms respond to PPI therapy. 
C 
 
 
B 
31,35,57,20
0 
34a. Patients with GERD symptoms and pathologic reflux exposure on 
pH (+/- impedance) monitoring off therapy and a negative reflux 
symptom association are eligible for anti-reflux surgery. 
34b. Patients with GERD symptoms and pathologic reflux exposure on 
pH (+/- impedance) monitoring off therapy and a negative reflux 
C 
 
 
C 
33,197,199 
symptom association are eligible for anti-reflux surgery, only if 
symptoms respond to PPI therapy. 
35. Patients with pathologic reflux exposure on pH (+/- impedance) 
monitoring on PPI who respond to baclofen therapy are good 
candidates for anti-reflux surgery. 
D 201,202 
36. A gastric emptying test for solid food is necessary to select GERD 
patients with concomitant dyspeptic symptoms for anti-reflux 
surgery. 
C 203-205 
37. If the gastric emptying test is abnormal for solid food, patients 
should not undergo an anti-reflux surgery. 
C 203,204,20
6,207 
 
  
Table 4: Summary of the ICARUS guidelines.  
Recommendations Based on statement(s) 
Anti-reflux surgery can be considered for patients with typical 
symptoms of heartburn, with a good response to PPIs. 
1 
Patients with functional heartburn and patients with eosinophilic 
esophagitis are poor candidates for anti-reflux surgery. 
4,6 
Patients with morbid obesity and patients with substance abuse are not 
excluded from anti-reflux surgery. 
9,11 
Endoscopy (during the last year) is mandatory prior to referral for anti-
reflux surgery. There is no need to wean the patient off PPI for 
endoscopy. 
13,14 
Patients with GERD symptoms and a hiatal hernia, Barrett’s esophagus, 
or erosive esophagitis grade B or higher at endoscopy are good 
candidates for anti-reflux surgery. 
15,16b,18 
Patients without erosive esophagitis are not excluded from anti-reflux 
surgery. 
17 
There is no need to obtain routine biopsies of the distal esophagus in 
patients considered for anti-reflux surgery. 
19 
A barium X-ray should be obtained in patients with suspicion of a hiatal 
hernia or short esophagus when considered for anti-reflux surgery. 
20 
Patients with GERD symptoms and a hiatal hernia on X-ray are good 
candidates for anti-reflux surgery. 
21,22 
Patients with GERD symptoms and a para-esophageal hernia on X-ray 
are good candidates for anti-reflux surgery in addition to para-
esophageal hernia repair. 
23 
A short esophagus on barium X-ray does not exclude the patient from 
anti-reflux surgery. 
24 
Esophageal manometry and esophageal pH-monitoring (+/- 
impedance) are mandatory prior to referral for anti-reflux surgery. The 
latter is preferentially done off PPI and in NERD patients. 
25,30,31 
Patients with normal pH-monitoring off PPI are poor candidates for 
anti-reflux surgery. 
32 
Response to baclofen does not enhance patient eligibility for anti-reflux 
surgery. 
35 
There is no need to assess gastric emptying rate in patients considered 
for anti-reflux surgery. 
36,37 
 
 
